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High Sodium Intake Strengthens the Association 
between Angiotensinogen T174M Polymorphism 
and Blood Pressure Levels among Lean Men 
and Women: a Community-Based Study
Kazumasa YAMAGISHI, Hiroyasu ISO, Takeshi TANIGAWA, Renzhe CUI, 
Minako KUDO, and Takashi SHIMAMOTO＊
Evidence on the effect of salt intake on the interaction between angiotensinogen (AGT ) T174M polymor-
phism and high blood pressure is sparse. We therefore conducted a large population-based cross-sectional
study of 2,823 men and women aged 30–74 in a Japanese farming community to examine associations be-
tween AGT polymorphism and blood pressure levels stratified by age (30–64 and 65–74), body mass index
(BMI; median), and salt intake (median) estimated by 24-h urine collection and dietary questionnaire. Our a
priori hypothesis is that individuals, particularly younger and non-overweight individuals, with the 174M al-
lele have elevated blood pressure levels in response to higher sodium intake, and thus the association be-
tween T174M polymorphism and blood pressure is more evident among individuals with higher sodium in-
take than those with lower sodium intake. There were no differences in systolic or diastolic blood pressure
levels (SBP or DBP) between the TT and TM＋MM genotype groups overall. However, the mean difference in
DBP between the TM＋MM and TT groups was ＋1.0 mmHg in subjects of younger age ( p＝0.06), ＋1.7
mmHg in non-overweight subjects (BMI＜23.5 kg/m2, p＝0.01), and ＋2.3 mmHg in younger and non-over-
weight subjects ( p＝0.002). Furthermore, among younger and non-overweight subjects, blood pressure 
differences were larger for those with higher urinary sodium excretion (＋3.1 mmHg, p＝0.03), those with a
higher sodium/potassium excretion ratio (＋4.1 mmHg, p＝0.007), those with higher present sodium in-
take score (＋3.0 mmHg, p＝0.003), and those with higher past sodium intake score (＋3.4 mmHg, p＜0.001).
In conclusion, AGT T174M polymorphism was associated with higher DBP levels in younger and non-over-
weight Japanese. This association was more evident among subjects with higher sodium intake.
(Hypertens Res 2004; 27: 53–60)
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gene and high blood pressure have been extensively studied,
but the findings have been inconsistent. A positive associa-
tion was initially found for Caucasians in both Utah and
Paris (1) and subsequently in other Caucasian populations
(2) and Japanese (3), but not for other Caucasians (4–6),
Introduction
The associations between T174M polymorphism (threonine-
to-methionine substitution) of the angiotensinogen (AGT)
Nigerians (7), Taiwanese (8), Arabs (9), or Chinese (10). A
study of a Canadian genetic isolate showed a positive associ-
ation between the AGT T174M genotype and hypertension
for men, but not for women (2). A large community-based
study of 9,100 Danish showed no association between
T174M polymorphism and high blood pressure, but double
homozygosity of 235T and 174T was associated with elevat-
ed blood pressure in women (11). The ECTIM study, which
examined the association stratified by body mass index (BMI),
showed that among subjects with BMI ＜26.0 kg/m2 there
was a 2.4-fold higher prevalence of high blood pressure in
those with the 174M allele than in those with the 174T
allele, but this trend was not apparent in subjects with BMI
≥ 26.0 kg/m2 (12). Previously, we conducted a community-
based case-reference study of 229 lean and non-drinking
Japanese hypertensives and 229 age-, sex- and community-
matched normotensives and showed a two-fold higher preva-
lence of the 174M allele among hypertensives than nor-
motensives (13).
As stated by Kato (14), large population studies and well-
characterized confounding factors will be needed to examine
the role of the specific gene polymorphism more thoroughly.
We suspected that the lack of association between T174M
polymorphism and hypertension in some of the previous
studies was due in part to the small number of subjects and
the potentially confounding factors of age, BMI, and sodium
intake, all of which affect blood pressure levels (15). Since
some previous studies showed that T174M polymorphism
was associated with hypertension primarily among young
and/or lean subjects (12, 13), we hypothesized that individu-
als, in particular young and non-overweight individuals, with
the 174M allele of AGT have elevated blood pressure levels
in response to a higher sodium intake, and thus the associa-
tion between T174M polymorphism and blood pressure is
more evident among individuals with a higher sodium intake
than those with a lower sodium intake. Therefore, we con-
ducted a large population-based observational study of 2,823
Japanese men and women to examine the associations be-
tween AGT polymorphism and blood pressure levels, strati-
fied by these confounding variables.
Methods
Subjects
The subjects were residents of the rural farming community
of Kyowa, Ibaraki Prefecture, central Japan (population
17,145 by the 2000 census). In this community, a general
stroke prevention program and annual cardiovascular risk
surveys have been conducted since 1981 (16). We included
in the present study individuals who participated in the 2001
survey and who were 30–74 years of age at that time (n＝
2,972). At the time of the survey, physician epidemiologists
explained the protocol to all participants, and obtained writ-
ten informed consent from 95% (n＝2,823) of them. The da-
ta of these 2,823 subjects were used in the analysis. The
study protocol was approved by the Medical Ethics Commit-
tee of the University of Tsukuba.
Population Surveys
Well-trained blood pressure observers measured arterial
systolic blood pressure (SBP) and fifth-phase diastolic blood
pressure (DBP) using standard mercury sphygmomanometers
on the right arm of quietly seated participants after an at least
5-min rest. When the first SBP reading was ≥ 140 mmHg
and/or the first DBP was ≥ 90 mmHg, the measurement was
repeated, and the second reading was used in the analysis.
We measured several potential confounders (17): BMI,
alcohol intake, urinary sodium and potassium excretion, and
sodium/potassium excretion ratio as estimated by 24-h urine
collection, and past and present sodium intake scores as
estimated by self-administered questionnaire. Height in
stocking feet and weight in light clothing were measured and
BMI was calculated as weight in kg divided by the square of
the height in m. Interviews were conducted to determine
usual weekly ethanol intake in go, a traditional Japanese unit
of volume corresponding to 23 g ethanol, which was converted
to g of ethanol per day.
All participants in the survey were asked to complete a
self-administered questionnaire to estimate both present and
past habitual sodium intake. Past sodium intake was defined
as the intake before the recognition of hypertension for hy-
pertensives, and approximately 10 years before the survey
for normotensives. A sodium intake score was calculated by
adding one point for each of 10 types of sodium intake: 1)
prefer salty-food, 2) use salty seasoning, 3) eat two or more
miso soup servings per day, 4) eat pickles two or more times
per day, 5) eat salty pickles, 6) put soy sauce on pickles, 7)
put soy sauce on meal, 8) eat salt-preserved food one or
more times per week, 9) eat salty noodle soup, and 10) do
not try to reduce salt intake. This scoring system was previ-
ously validated (13, 18), and was tested again in the present
study. Sex and age-adjusted mean 24-h sodium excretion
values across quintiles of the present sodium intake score
(n＝1,674) were 168, 180, 183, 195, and 203 mmol/l ( p for
trend ＜0.0001). The reproducibility of the present and past
sodium intake scores was also tested previously (13), and
was tested again in the present study by repeating the ques-
tionnaire after an interval of 1–2 years in a sub-sample (n＝
287); the Spearman correlation coefficient was 0.73 for the
present sodium intake score ( p＜0.001), and 0.62 for the
past sodium intake score ( p＜0.001). In the present study,
99% of the subjects completed the sodium intake question-
naire.
To estimate salt intake more accurately, some participants
collected one 24-h urine sample. The participants were asked
to collect all urine over a period of 24 h using a 3- or 4-l
plastic bottle. They were also asked to record the time of
each urination, whether they used inappropriate urine collec-
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tion methods, and the number of missed urine collections.
For each sample, total urine volume was measured, and then
the urine was transferred into 2-ml plastic vials and stored at
－80 ºC for a month until analysis. Sodium and potassium
concentrations were analyzed using an electrolyte analyzer
(Inflameter 775, Hitachi, Tokyo, Japan). Urine samples of
less than 500 ml or those with incomplete collections based
on the records were excluded from the analyses. Urine sodium
or potassium excretion was calculated as each concentration
(mmol/l) multiplied by the total urine volume (l), and
sodium/potassium ratio was calculated as the sodium
excretion divided by potassium excretion in mmol. Data of
potassium excretion and the sodium/potassium ratio were
used in secondary analyses, because potassium excretion is
strongly affected by sodium excretion. We included in the
analyses a total of 1,681 subjects who completed the 24-h
urine collection between 1982 and 2002.
DNA Genotyping
Genomic DNA was extracted from leukocytes in the buffy
coat of EDTA anticoagulated blood. AGT T174M genotypes
were determined by the allele-specific primer-polymerase
chain reaction (PCR) method using Taq DNA polymerase
(rTaq; Toyobo, Osaka, Japan) as described elsewhere (19).
The designed allele-specific sense primers were FITC-
CAGCTGCTGCTGTCCXCG for the 174T allele and TxR-
CAGCTGCTGCTGTCCXTG for the 174M allele labeled at
the 5′-end either with Texas red (TxR) or with fluorescein
isothiocyanate (FITC), and a 5′-biotin-end-labeled antisense
primer (biotin-GCCTGGGGCTGTGAACAC), where X rep-
resents an artificial mismatch base. To eliminate the possibil-
ity of a false positive result, we used an artificial mismatch
base (i.e., either C, G, or T) next to the allelic base, instead
of a matched base (A) (20). The amplification protocol con-
sisted of initial denaturation at 95 ºC for 5 min; 35 cycles of
denaturation at 95 ºC for 30 s, annealing at 60–65 ºC for 30 s,
and extension at 72 ºC for 30 s; and a final extension at 72 ºC
for 2 min. Fluorescence was measured with a microplate
reader (Fluoroscan Ascent; Dainippon Pharmaceutical, Osa-
ka, Japan) at excitation and emission wavelengths of 485 and
538 nm, respectively, for FITC and of 584 and 612 nm, re-
spectively, for TxR.
Statistical Analyses
The analysis of covariance and χ2 test were used to compare
sex-specific age-adjusted mean values and proportions of
risk characteristics. The χ2 test was used to examine whether
the genotype distributions differed from that expected from
Hardy-Weinberg equilibrium. The relation between geno-
type and blood pressure levels was examined by analysis of
covariance, stratified by age (30 to 64 and 65 to 74) and me-
dian BMI (23.5 kg/m2). Further analysis was performed strat-
ified by the medians of urinary excretion of sodium, potassi-
um, the sodium/potassium ratio, and present and past sodium
intake scores. The interaction between genotype and age,
BMI, and urinary variables/sodium intake scores in relation
to hypertension were examined using cross-product terms.
All statistical analyses were performed using SAS version
8.02 software (SAS Institute Inc., Cary, USA). All probabili-
ty values for statistical tests were two-tailed, and values of
p＜0.05 were regarded as statistically significant.
Results
The frequency of AGT genotypes was 79.6% for the TT
genotype, 19.1% for the TM genotype, and 1.3% for the MM
genotype. The sex-specific frequencies were 80.3%, 18.5%,
and 1.2% for men, and 79.2%, 19.5%, and 1.3% for women,
respectively. The genotype distribution was in Hardy-Wein-
berg equilibrium for men ( p＝0.85), women ( p＝0.86), and
total subjects ( p＝0.74). Because of the low prevalence of
the MM genotype, we combined the TM group and MM
group in the analyses. Table 1 summarizes the sex-specific
clinical and laboratory characteristics. The mean age was 59
years for men and 57 years for women. The prevalence of
hypertension was 43% for men and 35% for women, and the
mean 24-h urine sodium excretions were 199 mmol and
177 mmol, respectively.
Table 2 provides sex-specific age-adjusted characteristics
according to genotype. Mean age did not vary between the
TT and TM＋MM groups. For each sex and total samples,
the mean SBP and DBP values were not different between
the two groups. The prevalence of antihypertensive medica-
tion use and prevalence of hypertension also were not differ-
ent between the two groups. The other factors—i.e., BMI, al-
cohol intake, urine sodium excretion, urine potassium excre-
tion, urine sodium/potassium ratio, past and present sodium
intake score—did not vary between two groups.
The mean values of blood pressure levels adjusted for sex,
age, antihypertensive medication use, BMI, and alcohol con-
sumption are shown in Table 3 for each AGT genotype. For
total samples, there was no significant difference in blood
pressure levels between the TT group and TM＋MM group.
Among younger subjects aged 30–64, mean diastolic blood
pressure tended to be higher in the TM＋MM group than in
the TT group (＋1.0 mmHg, p＝0.06), but not among the
older subjects. The interaction of genotype with age was not
statistically significant ( p＝0.24). When stratified by BMI,
mean DBP was 1.7 mmHg higher in TM＋MM group than
in TT group in subjects with lower BMI (＜23.5 kg/m2, p＝
0.01), but not in those with higher BMI ≥ 23.5 kg/m2), and
the interaction between the two BMI groups was significant
( p＝0.04). These genetic associations among age or BMI
subgroup were primarily observed for women. There was no
association between the genotype and DBP levels when
stratified by urinary sodium, potassium excretion, sodium/
potassium excretion ratio, or salt intake scores (data not
shown). There was also no association between the genotype
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and SBP levels for total samples or any stratified subgroups.
Among the younger and non-overweight subjects, the as-
sociation between genotype and DBP levels was more evi-
dent and reached statistical significance for both sexes and
total subjects: the mean difference between the two genotype
groups was 3.3 mmHg for men ( p＝0.01), 1.8 mmHg for
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Table 1. Clinical and Laboratory Characteristics (Mean±SD and Proportion), Men and Women Aged 30–74 Years
Men Women Total
Number 1,048 1,775 2,823 
Age (years) 59.0±10.6 56.7±10.6 57.5±10.7
Systolic blood pressure (mmHg) 133.9±16.20 130.2±16.40 131.6±16.40
Diastolic blood pressure (mmHg) 80.7±10.2 76.8±10.1 78.3±10.3
Use of antihypertensive medication (%) 23.4 21.5 22.2 
Hypertension (%)† 43.1 34.6 37.8 
Body mass index (kg/m2) 23.9±3.00 23.5±3.30 23.6±3.20
Alcohol intake (g/day) 21.1±25.2 1.6±6.6 08.8±18.7
24-h urine collection (n) 676 1,005 1,681
Urine sodium excretion (mmol) 199.0±74.40 177.0±65.30 185.9±69.90
Urine potassium excretion (mmol) 54.1±20.1 54.5±20.0 54.4±20.1
Urine sodium/potassium ratio 3.88±1.32 3.47±1.27 3.63±1.31
Present sodium questionnaire completed (n) 1,038 1,764 2,802
Present sodium intake score 5.7±1.9 4.6±1.9 5.0±1.9
Past sodium questionnaire completed (n) 1,031 1,761 2,792
Past sodium intake score 6.8±1.8 5.9±2.0 6.3±2.0
†Hypertension was defined as systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg and/or use of
antihypertensive medication.
Table 2. Age-Adjusted Means and Proportions of Characteristics According to Angiotensinogen T174M Genotype in Men
and Women Aged 30–74 Years
Men Women Total
TT TM＋MM TT TM＋MM TT TM＋MM
Number 841 207 1,406 369 2,247 576
Age (years) 59.1 58.4 56.8 56.3 57.7 57.1
Systolic blood pressure (mmHg) 133.9 133.9 130.1 130.5 131.5 131.8
Diastolic blood pressure (mmHg) 80.7 80.9 76.6 77.5 78.1 78.8
Use of antihypertensive medication (%) 23.0 24.9 21.3 22.5 21.9 23.4
Hypertension (%)† 42.1 47.2 34.2 36.2 37.2 40.2
Body mass index (kg/m2) 23.9 23.8 23.4 23.6 23.6 23.7
Alcohol intake (g/day) 21.2 20.5 1.7 1.3 9.0 8.2
24-h urine collection (n) 540 136 793 212 1,333 348
Urine sodium excretion (mmol) 198.0 203.0 175.7 182.1 184.7 190.2
Urine potassium excretion (mmol) 53.7 55.6 54.2 55.9 54.0 55.8
Urine sodium/potassium ratio 3.88 3.88 3.46 3.47 3.63 3.63
Present sodium questionnaire completed (n) 832 206 1,401 363 2,233 569
Present sodium intake score 5.7 5.7 4.6 4.7 5.0 5.0
Past sodium questionnaire completed (n) 827 204 1,400 361 2,227 565
Past sodium intake score 6.9 6.6 5.9 5.9 6.3 6.2
†Hypertension was defined as systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg and/or use of
antihypertensive medication. No differences were observed among genotypes for all variables.
women ( p＝0.047), and 2.3 mmHg for total subjects ( p＝
0.002). Therefore, we used this population for the further
stratification analyses according to sodium excretion/intake
(Table 4). Mean DBP was 3.1 mmHg higher in the TM＋
MM group than in the TT group in subjects with higher uri-
nary sodium excretion (≥ 172.8 mmol/day, p＝0.03), but was
not significantly different among genotypes in those with
lower excretion (＜172.8 mmol/day). When stratified by uri-
nary potassium excretion, mean DBP was 2.1 mmHg higher
in the TM＋MM group than in the TT group in subjects with
lower urinary potassium excretion (＜51.3 mmol/day), al-
though this association did not reach the level of statistical
significance ( p＝0.15). Mean DBP was 4.1 mmHg higher in
the TM＋MM group than in the TT group in subjects with
higher sodium/potassium excretion ratios (≥ 3.46, p＝
0.007), but there was no significant difference among geno-
type groups in those with lower ratios (＜3.46). Mean DBP
was higher in the TM＋MM group than in the TT group in
subjects with higher sodium intake score for both the present
(3.0 mmHg, p＝0.003) and past (3.4 mmHg, p＝0.0004), but
this trend was less evident in subjects with lower sodium in-
take scores. The interaction between the genotype-blood
pressure relation and each of urinary sodium excretion, uri-
nary potassium excretion and present sodium intake score
did not reach the level of statistical significance, but the in-
teractions with the sodium/potassium excretion ratio and past
sodium intake score were of borderline significance ( p＝
0.049 and p＝0.051, respectively).
These results did not alter materially when excluding sub-
jects on antihypertensive medication (n＝627); the mean
DBP levels in the TM＋MM groups vs. TT groups were 78.1
vs. 77.4 mmHg ( p＝0.14) for total samples, 77.9 vs. 77.3
mmHg ( p＝0.25) for younger subjects, 76.1 vs. 74.7 mmHg
( p＝0.05) for non-overweight subjects, and 76.0 vs. 74.3
mmHg ( p＝0.02) for younger and non-overweight subjects.
Among younger and non-overweight subjects, the respec-
tive mean DBP levels were 77.6 vs. 74.8 mmHg ( p＝0.05)
for those with higher sodium excretion, 78.0 vs. 74.7 mmHg
( p＝0.02) for those with higher sodium/potassium ratio,
76.5 vs. 74.1 mmHg ( p＝0.02) for those with higher present
sodium intake score, and 76.9 vs. 74.0 mmHg ( p＝0.003) for
those with higher past sodium intake score (not shown in the
tables).
Discussion
The major finding of the present study was that there was a
significant association between AGT T174M polymorphism
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Table 3. Multivariate-Adjusted Blood Pressure Levels According to Angiotensinogen T174M Genotype, Stratified by Age and
Body Mass Index (BMI), in Men and Women Ages 30–74 Years
Men Women Total
TT TM＋MM p for TT TM＋MM p for TT TM＋MM p fordifference difference difference
Total 841 207 1,406 369 2,247 576
SBP (mmHg) 133.9 133.9 0.95 130.2 130.3 0.86 131.5 131.7 0.85
DBP (mmHg) 80.7 80.9 0.71 76.6 77.4 0.17 78.1 78.7 0.20
Stratified by age
30–64-years old 513 135 997 264 1,510 399
SBP (mmHg) 131.6 131.1 0.75 127.1 127.8 0.45 128.6 128.9 0.67
DBP (mmHg) 81.1 81.7 0.49 76.6 77.9 0.06 78.1 79.1 0.06
65–74-years old 328 72 409 105 737 177
SBP (mmHg) 137.6 138.6 0.66 137.6 136.8 0.65 137.6 137.6 0.99
DBP (mmHg) 80.0 79.7 0.84 76.5 77.0 0.66 78.0 78.2 0.85
Stratified by BMI
Below median (＜23.5 kg/m2) 372 101 758 178 1,130 279
SBP (mmHg) 131.0 130.5 0.78 126.1 126.8 0.59 127.7 128.0 0.77
DBP (mmHg) 77.8 79.2 0.18 74.0 75.9 0.02 75.3 77.0 0.01
Median or more (≥ 23.5 kg/m2) 469 106 648 191 1,117 297
SBP (mmHg) 136.2 137.2 0.52 134.7 134.4 0.79 135.3 135.4 0.89
DBP (mmHg) 83.0 82.5 0.66 79.6 79.3 0.75 81.0 80.6 0.56
Restricted to ages 30–64 and BMI ＜23.5 kg/m2
217 62 569 146 786 208
SBP (mmHg) 127.2 127.4 0.91 123.2 124.9 0.21 124.3 125.6 0.24
DBP (mmHg) 77.3 80.6 0.01 73.8 75.6 0.047 74.8 77.1 0.002
Blood pressures were adjusted for sex, age, antihypertensive medication use, BMI, and alcohol consumption. SBP, systolic blood pres-
sure; DBP, diastolic blood pressure.
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and DBP levels among younger non-overweight individuals
with high sodium intake, but not among individuals who
were older, who were overweight, or who had low sodium
intake. Our finding was consistent with a previous smaller
study (13) which showed a significant association between
the AGT T174M polymorphism and the prevalence of hy-
pertension among lean and non-drinking Japanese with high
sodium intake. The present large study extended the evi-
dence of the association between the 174M allele and high
blood pressure levels.
Furthermore, the relationship between the 174M allele and
blood pressure was more obvious among subjects aged ＜65
years than in older-age subjects. This may have been be-
cause younger individuals are more likely to be affected by
genetic factors rather than by environmental factors. Similar-
ly, this relationship became evident among non-overweight
subjects. Among subjects with BMI ＜26 kg/m2, the ECTIM
study showed a 2.4-fold higher prevalence of high blood
pressure in those with the 174M allele than in those with the
174T allele, but this trend was not apparent in subjects with
BMI ≥ 26 kg/m2 (12). These results suggest that high BMI
masks the relationship between the 174M allele and blood
pressure levels.
As anticipated, we observed clear associations between
AGT genotype and blood pressure levels among younger
non-overweight persons with higher sodium excretion and
higher past or present sodium intake scores. The positive as-
sociation among persons with higher sodium/potassium ex-
cretion ratio, which we determined in secondary analyses, al-
so supported our a priori hypothesis. These findings suggest
that it is necessary to consider age, BMI, and salt intake
when examining the association between AGT polymor-
phism and blood pressure levels. The lack of association be-
tween the T174M polymorphism and blood pressure levels
or hypertension in many previous studies (4–11, 21, 22) may
be related to a lack of adequate control for the influence of
these confounding factors.
The mechanism of T174M polymorphism on the elevated
blood pressure among individuals with high sodium intake is
uncertain. It is unlikely that a blood pressure increase is me-
diated by increased plasma AGT concentration, because pre-
vious studies have shown no association between T174M
polymorphism and plasma AGT concentrations (1, 5, 7, 11,
23). However, this does not negate a potential effect of
T174M polymorphism on local production of AGT, which
may affect blood pressure levels. It is also possible that other
functional polymorphisms, in linkage disequilibrium with
the T174M polymorphism, may contribute to the develop-
ment of salt-sensitive hypertension.
In our previous case-control study (13), we did not find
any association between M235T polymorphism and hyper-
tension even among persons with higher sodium intake, al-
though some previous studies have suggested an association
between M235T and salt-sensitive hypertension (24, 25).
Thus we did not analyze M235T polymorphism in the pre-
sent study. Since the prevalence of the 235T allele has been
shown to be high (approximately 70–80%) in Japanese (13),
we considered that the 174M allele, which was 5–15%
prevalent in Japanese, may be more effective than 235T for
detecting salt-sensitivity among non-Caucasian populations.
The strength of the present study was that we used a large
Table 4. Multivariate-Adjusted Blood Pressure Levels
According to Angiotensinogen T174M Genotype, Stratified
by Urinary Excretion of Sodium, Potassium, the Sodium/
Potassium Ratio, and Present and Past Sodium Intake
Scores, in Men and Women Aged 30–64 Years with Body
Mass Index (BMI)＜23.5 kg/m2
TT TM＋MM
p for
difference
Stratified by urinary sodium excretion
＜172.8 mmol/day 203 55
SBP (mmHg) 127.4 126.0 0.56
DBP (mmHg) 76.3 76.8 0.76
≥ 172.8 mmol/day 211 52
SBP (mmHg) 124.8 128.0 0.16
DBP (mmHg) 75.5 78.6 0.03
Stratified by urinary potassium excretion
＜51.3 mmol/day 202 58
SBP (mmHg) 125.6 129.0 0.12
DBP (mmHg) 76.1 78.2 0.15
≥ 51.3 mmol/day 212 49
SBP (mmHg) 126.4 124.9 0.52
DBP (mmHg) 75.6 77.7 0.17
Stratified by sodium/potassium excretion ratio
＜3.46 209 51
SBP (mmHg) 127.0 127.2 0.92
DBP (mmHg) 76.3 76.2 0.95
≥ 3.46 205 56
SBP (mmHg) 125.0 127.5 0.25
DBP (mmHg) 75.4 79.5 0.007
Stratified by present sodium intake score
＜5 336 93
SBP (mmHg) 125.3 125.9 0.70
DBP (mmHg) 75.3 76.8 0.20
≥ 5 447 113
SBP (mmHg) 123.6 125.4 0.21
DBP (mmHg) 74.4 77.4 0.003
Stratified by past sodium intake score
＜6 299 81
SBP (mmHg) 124.1 124.2 0.94
DBP (mmHg) 75.0 75.5 0.69
≥ 6 482 123
SBP (mmHg) 124.5 126.3 0.19
DBP (mmHg) 74.7 78.1 ＜0.0010
Blood pressures were adjusted for sex, age, antihypertensive
medication use, BMI, and alcohol consumption. SBP, systolic
blood pressure; DBP, diastolic blood pressure.
community-based sample. Furthermore, we obtained 24-h
urine collection samples and sodium intake scores, which al-
lowed us to test gene-environmental interactions of the AGT
T174M genotype with blood pressure levels.
There were several limitations in the present study. First,
because we used only single blood pressure measurement in
the analyses, measurement variability may have weakened
the genetic associations. However, since there were a large
number of subjects, we attained enough statistical power to
detect gene-blood pressure associations. Second, approxi-
mately 20% of subjects used antihypertensive medication,
which may have obscured the genetic effect of blood pres-
sure levels. However, since the prevalence of antihyperten-
sive medication use did not differ among the genotypes, the
possibility of such an influence is small. The exclusion of
subjects on antihypertensive medication did not alter the ge-
netic associations materially.
The public health implications of the present results war-
rant discussion. Differences in the mean DBP values be-
tween subjects with and without the 174M allele were 3–4
mmHg in younger non-overweight subjects whose salt intake
was high. These differences would seem to be small from the
viewpoint of clinical practice. However, a small difference in
the mean blood pressure levels over an entire population
translates to substantial effects on the incidence and mortality
of cardiovascular disease. A meta-analysis of nine prospective
observational studies demonstrated that a long-term differ-
ence of 5 mmHg in mean DBP was associated with reduc-
tions of 34% and 21% in stroke and coronary heart disease
risk, respectively (26). In our previous study of Japanese, a
difference of 5 mmHg in mean SBP was associated with a
15% reduction in stroke incidence and a 10% reduction in
coronary heart disease incidence (27). Therefore, salt reduc-
tion among members of salt-sensitive populations may have
a substantial impact on the prevention of cardiovascular dis-
ease.
In conclusion, the AGT 174M allele was associated with
higher DBP levels in younger and non-overweight Japanese
men and women. These associations were more evident
among persons with higher sodium intake. The present study
also showed the necessity of considering age, BMI, and salt
intake when estimating the genetic associations of AGT
polymorphism with high blood pressure.
Acknowledgements
The authors gratefully acknowledge Professor Aaron R. Folsom
of the University of Minnesota, USA for his valuable com-
ments, and Toshimi Kohigashi, Toshiko Suzuki, Mizue Fujii,
and Ai Ikeda for their technical assistance.
References
1. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al: Molecu-
lar basis of human hypertension: role of angiotensinogen.
Cell 1992; 71: 169–180.
2. Hegele RA, Brunt JH, Connelly PW: A polymorphism of
the angiotensinogen gene associated with variation in blood
pressure in a genetic isolate. Circulation 1994; 90: 2207–
2212.
3. Morise T, Takeuchi Y, Takeda R: Rapid detection and
prevalence of the variants of the angiotensinogen gene in
patients with essential hypertension. J Intern Med 1995;
237: 175–180.
4. Caulfield M, Lavender P, Farrall M, et al: Linkage of the
angiotensinogen gene to essential hypertension. New Engl J
Med 1994; 330: 1629–1633.
5. Schunkert H, Hense HW, Gimenez-Roqueplo AP, et al:
The angiotensionogen T235 variant and the use of antihy-
pertensive drugs in a population-based cohort. Hyperten-
sion 1997; 29: 628–633.
6. Tiret L, Blanc H, Ruidavets J-B, et al: Gene polymorphism
of the rennin-angiotensinogen system in relation to hyper-
tension and parental history of myocardial infarction and
stroke: the PEGASE study. J Hypertens 1998; 16: 37–44.
7. Rotimi C, Cooper R, Ogunbiyi O, et al: Hypertension,
serum angiotensinogen, and molecular variants of the an-
giotensinogen gene among Nigerians. Circulation 1997;
95: 2348–2350.
8. Chiang FT, Hsu KL, Tseng CD, et al: Molecular variant
M235T of the angiotensinogen gene is associated with
essential hypertension in Taiwanese. J Hypertens 1997; 15:
607–611.
9. Frossard PM, Hill SH, Elshahat YI, et al: Associations of
angiotensinogen gene mutations with hypertension and my-
ocardial infarction in a gulf population. Clin Genet 1998;
54: 285–293.
10. Niu T, Chen C, Yang J, et al: Blood pressure and the
T174M and M235T polymorphism of the angiotensinogen
gene. Ann Epidemiol 1999; 9: 245–253.
11. Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen
E, Jensen G, Tybjærg-Hansen A: Angiotensinogen poly-
morphism and elevated blood pressure in the general popu-
lation: the Copenhagen City Heart Study. Hypertension
2001; 37: 875–881.
12. Tiret L, Ricard S, Poirier O, et al: Genetic variation at the
angiotensionogen locus in relation to high blood pressure
and myocardial infarction: the ECTIM study. J Hypertens
1995; 13: 311–317.
13. Iso H, Harada S, Shimamoto T, et al: Angiotensinogen
T174M and M235T variants, sodium intake and hyperten-
sion among non-drinking, lean Japanese men and women. J
Hypertens 2000; 18: 1197–1206.
14. Kato N: Genetic analysis in human hypertension. Hyper-
tens Res 2002; 25: 319–327.
15. Yamori Y, Liu L, Mu L, et al: Diet-related factors, educa-
tional levels and blood pressure in a Chinese population
sample: finding from the Japan-China Cooperative Re-
search Project. Hypertens Res 2002; 25: 559–564.
16. Shimamoto T, Iso H, Tanigawa T, et al: Stroke, ischemic
heart disease and their risk factors in Kyowa town, Ibaraki,
Japan. Cardioangiology 2000; 48: 127–133 (in Japanese).
17. Yamagishi K, Iso H, Kitamura A, et al: Smoking raises the
risk of ischemic and total strokes in hypertensive men. Hy-
pertens Res 2003; 26: 209–217.
Yamagishi et al: AGT Polymorphism, Sodium Intake, and Blood Pressure 59
18. Iso H, Shimamoto T, Yokota K, Sankai T, Jacobs DR Jr,
Komachi Y: Community-based education classes for hyper-
tension control: a 1.5-year randomized controlled trial. Hy-
pertension 1996; 27: 968–974.
19. Yamada Y, Izawa H, Ichihara S, et al: Prediction of the risk
of myocardial infarction from polymorphisms in candidate
genes. New Engl J Med 2002; 347: 1916–1923.
20. Takarada Y: Analysis for SNPs using allele specific primer.
Upload 2002; 66: 8–9 (in Japanese).
21. Fernández-Llama P, Poch E, Oriola J, Botey A, Rivera F,
Revert L: Angiotensinogen gene M235T and T174M poly-
morphism in essential hypertension: relation with target or-
gan damage. Am J Hypertens 1998; 11: 439–444.
22. Jeunemaitre X, Inoue I, Williams C, et al: Haplotypes of
angiotensinogen in essential hypertension. Am J Hum Genet
1997; 60: 1448–1460.
23. Brand E, Chatelain N, Paillard F, et al: Detection of puta-
tive functional angiotensinogen (AGT) gene variants con-
trolling plasma AGT levels by combined segregation-link-
age analysis. Eur J Hum Genet 2002; 10: 715–723.
24. Hunt SC, Geleijnse JM, Wu LL, Witteman JC, Williams
RR, Grobbee DE: Enhanced blood pressure response to
mild sodium reduction in subjects with the 235T variant of
the angiotensinogen gene. Am J Hypertens 1999; 12: 460–
466.
25. Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T:
Salt sensitivity of Japanese from the viewpoint of gene
polymorphism. Hypertens Res 2003; 26: 521–525.
26. MacMahon S, Peto R, Cutler J, et al: Blood pressure,
stroke, and coronary heart disease: part 1, prolonged differ-
ences in blood pressure: prospective observational studies
corrected for the regression dilution bias. Lancet 1990; 335:
765–774.
27. Iso H, Shimamoto T, Yokota K, et al: Changes in 24-hour
urinary excretion of sodium and potassium in a community-
based health education program on salt reduction. Jpn J
Public Health 1999; 46: 894–903 (in Japanese).
60 Hypertens Res Vol. 27, No. 1 (2004)
